Skip to main content

Table 4 Association between biomarker values and the long-term outcome measures

From: The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial

   Long-term outcome (5 years after treatment)
   Yearly radiographic progression rate Time-averaged DAS28
Biomarker   No. B 95% CI No. B 95% CI
C2C Baseline 126 0.08 -0.28 to 0.44 120 0.11 -0.25 to 0.47
  1 yr 126 -0.23 -0.67 to 0.20 120 0.18 -0.25 to 0.61
  Change 126 -0.59 -1.14 to -0.03 120 0.04 -0.52 to 0.60
C1,2C Baseline 126 0.47 0.001 to 0.95 120 0.10 -0.40 to 0.60
  1 yr 127 0.14 -0.36 to 0.65 121 0.22 -0.29 to 0.73
  Change 126 -1.00 -1.80 to -0.20 120 0.33 -0.52 to 1.18
CS846 Baseline 127 -0.06 -0.27 to 0.16 121 -0.08 -0.29 to 0.14
  1 yr 126 -0.07 -0.29 to 0.15 120 -0.03 -0.26 to 0.20
  Change 126 -0.01 -0.23 to 0.21 120 0.05 -0.18 to 0.28
CPII Baseline 124 0.14 -0.07 to 0.35 118 -0.05 -0.26 to 0.17
  1 yr 125 0.13 -0.09 to 0.34 119 0.10 -0.12 to 0.31
  Change 122 -0.07 -0.34 to 0.20 122 0.30 0.02 to 0.57
ZC2C + ZC1,2C Baseline 125 0.07 -0.02 to 0.17    
  1 yr 126 0.01 -0.11 to 0.08    
  Change 126 -0.13 -0.22 to -0.04    
  1. Biomarkers with B (95% confidence interval (CI)) values, which are shown in Bold type have a P value < 0.05 and have been included in the multiple regression analyses. Biomarkers values were determined at baseline, at 1 year, and the change between 1 year and baseline. Next are the sum and ratio scores (based on Z-values), determined when individual biomarkers had a significant association with the outcome in the initial analysis.
  2. DAS28, disease activity score based on 28 joints; n, number of patients investigated; 95% CI, 95% confidence interval.